Percutaneous isolated hepatic perfusion with melphalan (M-PHP) is a minimally invasive and repeatable technique for the treatment of malignant liver tumors. The superiority of M-PHP over standard available therapy has been demonstrated in a randomized controlled multicenter phase III trial for patients with liver metastases from cutaneous and ocular melanoma (1). In the Netherlands, M-PHP is now regarded as first-line therapy in patients with liver metastases from ocular melanoma, as such patients often present with unresectable metastases confined to the liver and effective systemic therapies are not available (2-4).
Percutaneous isolated hepatic perfusion with melphalan (M-PHP) is a minimally invasive and repeatable technique for the treatment of malignant liver tumors. The superiority of M-PHP over standard available therapy has been demonstrated in a randomized controlled multicenter phase III trial for patients with liver metastases from cutaneous and ocular melanoma (1). In the Netherlands, M-PHP is now regarded as first-line therapy in patients with liver metastases from ocular melanoma, as such patients often present with unresectable metastases confined to the liver and effective systemic therapies are not available (2) (3) (4) .
PURPOSE
In patients undergoing percutaneous liver perfusion with melphalan (M-PHP), the presence of variant hepatic arteries (HAs) may require catheter repositioning and thus prolong procedure time. Coil-embolization of variant HAs may enable M-PHP with a single catheter position as occlusion of variant HAs results in redistribution of flow through preexisting intrahepatic arterial collaterals. We aimed to evaluate whether redistribution of flow has any negative effect on therapeutic response in ocular melanoma patients undergoing M-PHP.
METHODS
We retrospectively analyzed pretreatment angiograms in all 32 patients that underwent M-PHP between January 2014 and March 2017 for unresectable liver metastases from ocular melanoma. Patients that underwent embolization of a variant left HA (LHA) or middle HA (MHA) during pretreatment angiography followed by at least one technically successful M-PHP were included for further analysis. Redistribution of arterial flow was evaluated on angiography and cone-beam CT (CBCT) images. In each patient, tumor response in liver segments with redistributed blood flow was evaluated using RECIST 1.1 and mRECIST, and then compared with tumor response in segments without flow redistribution. Follow-up scans were reviewed to evaluate progression of liver metastases.
RESULTS
A total of 12 patients were included. Replaced LHA embolization resulted in redistribution of flow to segment(s) 2 (n=3), 2 and 3 (n=5), and 2, 3 and 4 (n=2). MHA embolization resulted in redistribution of flow to segment 4 (n=2). Successful redistribution was confirmed by angiography and/or CBCT in all patients. Tumor response was similar for redistributed and non-redistributed liver segments in 8 out of 9 patients (89%) according to RECIST 1.1, and in 7 out of 8 patients (88%) according to mRECIST. In three patients, tumor response was not evaluable according to RECIST 1.1 or mRECIST as metastases were too small to be categorized as target lesions (n=1), or target lesions were confined to non-redistributed segments (n=2). In one patient, tumor response was not evaluable according to mRECIST as target lesions in the redistributed segments were hypovascular. After a median follow-up time of 17.1 months (range, 9.1-38.5 months), hepatic progression was seen in 9 out of 12 patients with a median time to progression of 9.9 months (range, 2.5-17.7 months). Progression of liver metastases was never seen only in the redistributed liver segments.
CONCLUSION
Flow redistribution in liver segments by coil-embolization of variant HAs is a feasible technique that does not seem to compromise tumor response in patients undergoing M-PHP.
A common complication of M-PHP is bone marrow suppression resulting in anemia, thrombocytopenia, and/or neutropenia. This is caused by the inability of hemofiltration cartridges to extract all melphalan allowing a limited amount of chemotherapeutics to reach the systemic circulation (5, 6) . In an attempt to reduce bone marrow suppression, a new second-generation filter (GEN 2 filter) was developed by Delcath Systems. Although the mean filter extraction rate of the GEN 2 filter is indeed higher compared to first-generation filters (86% vs. 77%), severe hematologic toxicity is still reported in patients that underwent M-PHP using the GEN 2 filter (5-7). Additionally, it was demonstrated that the extraction rate of the GEN 2 filter decreases over time, probably due to saturation of the filter (6). This means that patients with a prolonged extracorporeal filtration time may be at risk of increased systemic exposure to melphalan. Furthermore, a longer extracorporeal filtration time results in a prolonged cardiac strain, an increased risk of hemolysis, and hypothermia. Therefore, extracorporeal filtration time should be limited when possible.
Prolonged extracorporeal filtration time can result from the presence of variant hepatic arterial anatomy as repositioning of the infusion catheter may be required to deliver chemotherapy to all liver metastases. We address this problem by using so-called "redistribution of flow" in which variant hepatic arteries (HAs) are embolized with coils, after which perfusion of liver segments is taken over by preexisting intrahepatic arterial collaterals originating from an adjacent segment. This technique is well studied in patients with liver tumors treated with radioembolization (8-11) and hepatic arterial infusion chemotherapy (12) (13) (14) (15) (16) . Two studies on yttrium-90 ( 90 Y) radioembolization found a similar tumor response for both redistributed and non-redistributed segments in 92%-96% of patients (9, 11). Although it is also a well-established technique in hepatic arterial infusion chemotherapy, concern has been raised by some that redistribution of flow may have an unfavorable effect on tumor response (17, 18) . The effect of flow redistribution on therapeutic response of liver metastases treated with M-PHP needs further investigation.
We hypothesized that flow redistribution in the liver by coil-embolization of variant HAs prior to M-PHP has no adverse effect on therapeutic response in patients with liver metastases from ocular melanoma. In order to demonstrate this, we retrospectively reviewed our patient series.
Methods

Study design and population
In this retrospective study, we reviewed pretreatment angiograms in all 32 patients that underwent M-PHP between January 2014 and March 2017 as a treatment of unresectable liver metastases from ocular melanoma. Of these 32 patients, 20 were excluded and 12 patients (median age, 62 years; age range, 44-71 years) were found eligible for further analysis in this study. Exclusion criteria were the absence of an embolized variant HA (n=18) and no technically successful M-PHP (n=2), due to cardiac ischemia and heparin-induced thrombocytopenia.
All patients received their treatment as part of a prospective phase II trial, and therefore had given their informed consent. Approval was obtained from the local medical ethics committee.
Pretreatment angiography and M-PHP
Prior to M-PHP, all patients underwent selective angiography of the celiac trunk in order to determine the hepatic arterial circulation and formulate the best strategy for infusion of melphalan. Catheterization was performed using a 5F catheter (Radifo-cus® angiographic catheter general-visceral cobra, Terumo or Cordis® angiographic catheter C2, Cordis Corporation) with a 2.4 F or 2.7 F Progreat (Terumo) microcatheter. If deemed necessary, hepatico-enteric anastomoses, such as the gastroduodenal or right gastric artery, were embolized to prevent inadvertent leakage of melphalan during M-PHP. Occlusion of replaced left HAs (LHAs) or middle HAs (MHAs) was performed if: 1) perfusion of the entire liver was not feasible using a single infusion site, and 2) repositioning of the catheter was considered challenging and/ or time-consuming. Embolization was performed with 2 to 8 mm detachable coils (Interlock, Boston Scientific). Angiography was performed using a Philips AlluraClarity Interventional X-ray System with Clarity IQ technology (Philips Medical Systems). Performance of C-arm cone-beam CT (CBCT) to ensure enhancement of the entire liver and exclude vascular tumor supply from extrahepatic collaterals was left to the discretion of the interventional radiologist. CBCT images were acquired during a 10-second rotation of the Philips AlluraClarity C-arm (300 images, 240° arc). Tube voltage was 120 kV, tube current was automatically adjusted to each patient by the system (range, 50-325 mA). Contrast medium (Iohexol, 300 mg iodine/ mL, Omnipaque 300, GE Healthcare) was injected at a flow rate of 1-2 mL/s for lobar injections and 2-3 mL/s for injections from the proper or common hepatic artery. The injected contrast volume was calculated using the following equation: Volume = (scan delay + scan time) × flow rate with the scan delay being the time between the start of injection and tumor enhancement at angiography. Initial M-PHPs were performed approximately one week after angiography. Details of the procedure were described elsewhere (19) . As per protocol, most patients underwent two cycles of M-PHP at 6-9 weeks interval with 3 mg melphalan/kg and maximum dose of 220 mg. No CBCT was performed at the time of the actual M-PHP treatment.
Imaging, image interpretation, and evaluation of response
Pretreatment angiograms were studied and types of embolized variant HAs were recorded. Whether the embolization resulted in successful redistribution of flow was evaluated on angiography and CBCT. Successful redistribution was defined as enhancement of all segmental HAs on angiography and enhancement of all liver segments on CBCT.
Main points
• Percutaneous hepatic perfusion with melphalan (M-PHP) is an effective treatment for liver metastases from ocular melanoma.
• Prolonged extracorporeal filtration time may lead to increased systemic exposure to melphalan and subsequent bone marrow suppression.
• In patients with aberrant hepatic arteries (HAs) extracorporeal filtration time is prolonged as catheter repositioning is required to treat the entire liver.
• Coil-embolization of variant HAs causes redistribution of flow and subsequent melphalan infusion using a single catheter position.
• Our study shows that flow redistribution in liver segments by embolization of a variant left or middle HA does not affect therapeutic response of metastases from ocular melanoma when treated with M-PHP.
All patients underwent a contrast-enhanced CT of chest and abdomen (arterial and portovenous phase) 5-10 weeks after the first and second M-PHP. After this, follow-up contrast-enhanced CT was performed every three months. An additional MRI of the liver was performed in patients with lesions that were difficult to visualize on contrast-enhanced CT.
Tumor response was evaluated according to Response Evalution Criteria in Solid Tumors 1.1 (RECIST 1.1) and modified RECIST (mRECIST). In each patient, the response of target lesions previously supplied by a variant HA and now depending on intrahepatic arterial collaterals, was compared with the response of target lesions in segments not depending on collaterals (Fig. 1) . Retrospective consensus reading of scans was performed by two readers. A maximum of two target lesions were selected in both liver segment(s) with flow redistribution and non-redistributed segments (i.e., a maximum of four target lesions per liver). A maximum of two target lesions was chosen in order to have: 1) a scoring system similar to RECIST 1.1. and mRECIST, 2) consistent response evaluation in different patients (the number of lesions varied considerably between patients), 3) consistent response evaluation between segments with and without flow redistribution (in most cases more lesions in segments without flow redistribution), and 4) for practical reasons (most patients presented with numerous lesions).
Lesions were considered as target lesions if their longest diameter was ≥10 mm and borders were defined well enough to allow reliable measurement.
Scans performed during further follow-up were reviewed to evaluate progression of liver metastases. In case of hepatic progression, we determined whether progression (i.e., growth of existing lesions or new lesions) occurred in the redistributed and/or non-redistributed liver segments.
Results
All patients had bilobar multifocal disease and underwent a median of two M-PHP cycles (range, 1-4). Patient demographics and metastatic details are summarized in Table 1 .
Replaced LHA embolization was performed in 10 out of 12 patients, leading to redistribution of flow in liver segment 2 (n=3), segments 2 and 3 (n=5), or segments 2, 3 and 4 (n=2). Two patients underwent embolization of a segment 4 artery. Fig. 2 shows schematic diagrams of various types of variant HAs that were embolized.
Post-embolization angiography showed successful redistribution of flow in all patients (Fig. 3) . This was confirmed by CBCT in 9 out of 12 patients. CBCT images were not available for two patients (no. 3 and 11), and in one patient (no. 7) CBCT showed no enhancement in the redistributed segments. This was probably due to the scanning delay being too short which resulted in acquisition of the images prior to contrast medium arrival.
Tumor response in both redistributed and non-redistributed liver segments was not evaluable according to RECIST 1.1 and mRECIST in 3 out of 12 patients (Table 2) .
Reasons were the absence of target lesions with all metastases measuring <10 mm (n=1), and target-lesions only observed in non-redistributed segments (n=2). In one patient, tumor response was not evaluable according to mRECIST, because not all target lesions were hypervascular.
Target tumor response in redistributed and non-redistributed liver segments was evaluable according to RECIST 1.1 and mRE-CIST in 9 out of 12 patients (Table 2, Fig. 4 ). According to RECIST 1.1, partial response was seen in both redistributed and non-redistributed liver segments in 8 out of 9 patients (89%). A discrepancy in radiologic response was seen in one patient: partial response in the redistributed liver segment compared Embolization of variant hepatic arteries in patients undergoing melphalan perfusion treatment Figure 1 . Assessment of the effect of flow redistribution on therapeutic response of liver metastases is schematically depicted in this liver in which a variant left hepatic artery (LHA) is embolized (dotted). If all tumors responded positively (top), redistribution seemed to have no negative effect. If tumors in non-redistributed segments responded positively but tumors in redistributed segments showed no therapeutic response (middle), we interpreted this as evidence that redistribution had a negative effect. If all tumors uniformly progressed (bottom), the effect of redistribution would not be evaluable because even lesions in the non-redistributed segments showed no therapeutic response suggesting therapy resistance.
with stable disease in non-redistributed liver segments. According to mRECIST, a similar tumor response in redistributed and non-redistributed segments was observed in 7 out of 8 patients (88%). Complete response and progressive disease were seen in 5 and 2 patients, respectively. A discrepancy in radiolog ic response was seen in one patient: complete response in the redistributed liver segment compared with partial disease in non-re distributed liver segments.
Three out of 12 patients (patient no. 2, 3, and 10) received an MRI prior to treatment and at follow-up imaging, as their liver lesions were not well visualized on contrast-enhanced CT. In the other 9 patients, contrast-enhanced CT was sufficient to image liver lesions and evaluate tumor response. Seven out of 12 patients (patient no. 3-7, 11 and 12) underwent an additional [18F]-fluorodeoxyglucose-positron emission tomography combined with unenhanced CT (FDG-PET/CT) at some point during the follow-up. The median time period between first M-PHP and the performance of the FDG-PET/CT was 7.8 months (range, 4.0-37.3 months).
After a median follow-up time of 17.1 months (range, 9.1-38.5 months), progression of liver metastases was seen in 9 out of 12 patients with a median time to progression of 9.9 months (range, 2.5-17.7 months). Progression was either seen only in liver segments without flow redistribution (n=5) or in both redistributed and non-redistributed segments (n=4) ( Table 3 ).
Discussion
This study shows that in patients with liver metastases from ocular melanoma treated with M-PHP, tumor response in liver segments with redistributed arterial flow is not compromised compared with tumor response in non-redistributed liver segments. This implies that coil-embolization of replaced LHAs or MHAs in order to simplify the administration of melphalan has no adverse effect on therapeutic response in these patients. Coil-embolization of replaced right HAs was not performed, as they were considered as the dominant artery to supply the liver in all cases. We found it was uncertain whether whole liver perfusion through the LHA would be sufficient and not compromise tumor response.
Approximately 40% of all ocular melanoma patients will develop metastases within 10 years after diagnosis of the primary tumor (20) . Liver metastases occur in 93%-95% of patients with metastatic ocular melanoma, often affecting both liver lobes (20) (21) (22) . Effective systemic therapies are lacking and therefore patients with liver-dominant disease should be considered for liver-directed therapies such as transarterial (chemo-)embolization, radioembolization and isolated hepatic perfusion (IHP). M-PHP is a novel minimally invasive and repeatable alternative to IHP and is performed more and more in these patients (1, (23) (24) (25) (26) (27) (28) . In a recently conducted randomized controlled multicenter phase III trial, treatment with M-PHP was compared with best available care in patients with liver metastases from ocular melanoma (1). It was demonstrated that M-PHP significantly prolongs both hepatic progression-free survival (7.0 vs. 1.6 months) and overall progression-free survival (5.4 vs. 1.6 months).
Redistribution of arterial flow has been well established in patients with liver tumors treated with 90 Y radioembolization and is used to limit the number of administration sites, improve selectivity of treatment, and reduce the risk of nontar- Table 1 . Demographic data and metastatic details in patients with an embolized HA and ≥1 technically successful M-PHP (n=12)
